Genomes of all living organisms are constantly injured by endogenous and exogenous agents that modify the chemical integrity of DNA and in turn challenge its informational content. Despite the efficient action of numerous repair systems that remove lesions in DNA in an error-free manner, some lesions, that escape these repair mechanisms, are present when DNA is being replicated. Although replicative DNA polymerases are usually unable to copy past such lesions, it was recently discovered that cells are equipped with specialized DNA polymerases that will assist the replicative polymerase during the process of Translesion Synthesis (TLS). These TLS polymerases exhibit relaxed fidelity that allows them to copy past lesions in DNA with an inherent risk of generating mutations at high frequency. We present recent aspects related to the genetics and biochemistry of TLS and highlight some of the remaining hot topics of this field.
Introduction
The aim of this review is to discuss our current knowledge of the mechanisms that convert DNA lesions into mutations during the process of DNA replication. Indeed, most if not all point mutations are fixed in the newly synthesized strand when DNA synthesis proceeds on templates containing lesions. DNA replication normally proceeds with high fidelity, high velocity and high processivity on undamaged DNA templates. However, when an unusual base is present in the template (i.e. a DNA lesion), replication is temporarily hampered. We will discuss the mechanisms by which cells manage to replicate damaged DNA templates despite the extraordinary chemical diversity of existing DNA lesions that DNA polymerases have to deal with. It is therefore not surprising that the process of Translesion synthesis (TLS) is error-prone.
A glance at the diversity of DNA lesions (Figure 1) Within the context of this review we will define DNA lesions as chemically altered bases, although the sugarphosphodiester backbone may also suffer various damages. Lesions may be spontaneous (i.e. depurinations), induced endogenously (i.e. by reactive oxygen species), induced by radiations (UV light, X-rays) or by chemicals. Treatments that induce DNA lesions cause mutations and cancer and are therefore referred to as mutagens or carcinogens. Carcinogens fall into large chemical families of compounds such as aromatic amides, polycyclic hydrocarbons, nitrosamines. Carcinogens are not necessarily synthetic, for example, some are natural plant metabolites (i.e. Aflatoxin B1). In addition, some drugs used in cancer chemotherapy such as platinum derivatives form covalent DNA adducts and as such are also carcinogens.
The challenge of copying lesion-containing DNA templates, a process called Translesion Synthesis (TLS) (Figure 2) DNA polymerases are highly specialized enzymes capable of replicating DNA templates that contain the four normal nucleotides A, G, C or T. When instead a lesion (X) is present in the template, most DNA polymerases will experience difficulties in inserting one of the four normal dNTPs across the damaged base. Even when insertion has occurred, the resulting primer terminus is likely to be distorted, thus compromising efficient extension. Moreover, the 3'?5' exonuclease activity (proofreading function) present in all replicative DNA polymerases is likely to remove the nucleotides in the primer strand in the vicinity of the lesion (dotted arrows in Figure 2 ) thus triggering futile cycles of insertion-excision steps. Both insertion and extension steps will slow down the replication process in the vicinity of the lesion triggering pause sites. The duration of a pause site will depend upon many factors such as the chemical nature of the lesion, its sequence context and upon the DNA polymerase that is involved. The process of TLS is necessarily error-prone. Indeed, as most lesions literally destroy the coding properties of the preexisting base, when insertion of a nucleotide across from the lesion site occurs, it is likely to be different from that expected if the template base were not damaged, thus yielding a base substitution. Moreover, if the base inserted across from the lesion site is complementary to the next template base, a primer template misalignment event (slippage) may occur, generating a frameshift mutation (Figure 2 , right side).
The 'old' paradigm of TLS (until 1999) Among the most common lesions that have been studied, i.e. UV induced lesions, AP sites, AAF adducts, all were known to block DNA synthesis in vitro with the commonly available DNA polymerases Figure 1 A glance at the diversity of DNA lesions. Lesions are highlighted by the pink area. (a) Abasic site, a common lesion that can be formed in a variety of ways: spontaneous or alkylation induced depurination, repair intermediates. (b) 8-oxo-guanine, a common lesion generated by reactive oxygen. (c) The T(6-4)T photoproduct is a minor but highly mutagenic lesion induced by UV-light. It cross links two adjacent thymine residues via a covalent 6-4 bond. (d) B(a)P-N2-dG, the major guanine adduct formed by benzo(a)pyrene, a common polycyclic hydrocarbon found in cigarette smoke and other combustion residues. (e and f) dG-C8-AAF and dG-C8-AF are the major adducts formed by an aromatic amine N-2-acetylaminofluorene (AAF), a strong liver carcinogen. The two adducts only differ by an acetyl group. However they impose quite different DNA distortions and induce very distinct mutation patterns. (g) dG-N7-AFB1, is the major guanine adduct of a potent hepatocarcinogen. Aflatoxin B1, is a metabolite produced by a mold that grow on peanuts. (h) cis-Pt-d(GpG) is an intrastrand cross link produced by the drug cisplatin that is used in human cancer chemotherapy Translesion synthesis in vivo V Pagè s and RPP Fuchs such as DNA polymerases I and III from E. coli, or phage T4 and T7 DNA polymerases. In striking contrast, these lesions were known to be bypassed in cells. Evidence for in vivo bypass mainly relied on the observation that lesions induce point mutations and leave a specific 'mutagenic signature'. Indeed, when forward mutation spectra were determined, given lesions were found to induce specific mutations (i.e. transitions versus transversions, frameshift mutations) (Miller, 1983) . Moreover, frameshift mutations frequently occur at high frequencies within specific sequence contexts, known as mutation hot spots thus leaving a strong mutagenic imprint (Fuchs et al., 1981) . Genetic studies identified loci such as the umuDC operon (Kato and Shinoura, 1977; Steinborn, 1978) in E. coli and the various REV genes (Lemontt, 1971) in S. cerevisiae which abolish induced mutagenesis when mutated. It therefore became clear that mutagenesis was an active process involving specific proteins in addition to the replicative DNA polymerase. The common paradigm that emerged from these studies was that mutagenesis resulted from a transient alteration of the properties of the replicative DNA polymerase by means of accessory factors. Although the biochemistry of the process remained obscure it was usually believed that these factors may in fact lower the stringency of the replicative DNA polymerase and/or inhibit its proofreading function in order to prevent the futile insertion-excision cycles across lesion sites as discussed above. Curiously, the simple idea that the genes involved in induced mutagenesis could actually encode specialized DNA polymerases per se was not seriously considered, the reason probably being the lack of amino-acid homology of these genes to the known DNA polymerases. This situation rapidly evolved with the discovery that some of the products of the genes involved in mutagenesis exhibit DNA polymerase activity in vitro.
The 'DNA polymerase switch model' for TLS and mutagenesis ( Figure 3 )
The first hint that gene products involved in mutagenesis encode proteins endowed with DNA polymerase activity came from the studies of C Lawrence and D Hinckle on Rev1p and Rev3p/Rev7p proteins from S. cervisiae (Nelson et al., 1996a,b) . It was indeed shown that Rev1p encodes a deoxycytidyl transferase while the Rev3p/Rev7p heterodimer (Pol x) is a template-directed DNA polymerase. In contrast to the REV3 gene, which is a member of the B-family of DNA polymerases, the REV1 gene exhibits no sequence homology to the classical DNA polymerases, but was instead described as having 25% of identity with the umuC gene in E. coli (Larimer et al., 1989) . During the year 1999 and in chronological order of discovery, the DNA polymerase activities of the S. The DNA template contains a DNA lesion (X) that imposes a structural distortion upon the DNA backbone. TLS can be viewed in at least two steps, Insertion and Extension. At the Insertion step, the challenge for a DNA polymerase is to insert one of the four common dNTP's (pink nucleotides) across lesion X. As in most cases, none of the dNTP's will be able to 'pair' with X, the 'least worse' nucleotide will be added to the primer. The resulting primer terminus will be distorted, thus defying polymerases to perform the extension step(s). In addition, the proofreading function that is part of all replicative DNA polymerases will often excise the newly incorporated nucleotide (dotted arrow), thus initiating futile addition-excision cycles. TLS is often mutagenic, it can induce base substitutions or frameshift mutations as shown. Frameshift mutations often result from a primer template slippage event, when the nucleotide inserted across the lesion (T, in this example) is complementary to the next base in the template cervisiae protein Rad30p (Pol Z) (Johnson et al., 1999b) , the E. coli dinB gene product (Pol IV) (Wagner et al., 1999) and umuDC gene product (Pol V) (Tang et al., 1999; Reuven et al., 1999) were described. Together with REV1, RAD30, dinB and umuDC are the founding members of the four branches of the Y-super-family of DNA polymerases (Ohmori et al., 2001) . In general, these polymerases have in common several properties: ability to copy lesion containing DNA, low fidelity on non-damaged templates, propensity to use mismatched primer termini. These polymerases lack proofreading function, are usually slow enzymes when compared to the classical polymerases and exhibit little processivity. Recent crystallographic data have shown that DNA polymerases of the Y-family overall adopt a 'right hand' structure similar to that found for the classical DNA polymerases (Ling et al., 2001; Silvian et al., 2001; Trincao et al., 2001; Zhou et al., 2001) . However, shorter 'fingers' and 'thumb' provide a wider open active cleft that is able to accommodate more easily various distortions. The structure and biochemistry of the Y-family DNA polymerases will not be discussed further within the context of this review. It should also be noted that not all polymerases known to participate in TLS and mutagenesis belong to the Y-family. For instance, Pol z in yeast (for a recent review, Lawrence, 2002) and Pol II in E. coli (Napolitano et al., 2000) also take part in lesion bypass. In addition, as discussed below, replicative DNA polymerases may perform bypass of bulky lesions in vivo on their own, further illustrating the notion that there is no strict barrier among bypass and classical DNA polymerases.
With the discovery of DNA polymerases specialized in TLS, it became clear that lesion bypass and mutagenesis will entail several DNA polymerase transactions, the replicative DNA polymerase being transiently replaced in the vicinity of the lesion by one (or several) specialized polymerases before resuming high fidelity replication. This new paradigm for TLS/ mutagenesis was dubbed the 'DNA polymerase switch model' (Figure 3) . Figure 3 The 'DNA polymerase switch model' for TLS and Mutagenesis . This cartoon shows the replicative DNA polymerase (yellow) blocked at a template lesion site. Cells contain several different DNA polymerases (green, blue) that transiently replace the replicative DNA polymerase. After a short patch of synthesis in the vicinity of the lesion (red patch), the replicative DNA polymerase resumes high fidelity and processive synthesis
How to analyse TLS and mutagenesis in vivo?
Numerous studies published since the discovery of the bypass polymerases involve primer extension reactions using synthetic oligonucleotides carrying a single lesion. Although such studies provide clues as to the efficiency and specificity of bypass of a given lesion by a given polymerase, their overall physiological significance is questionable. Indeed, in vivo multiple DNA polymerases and various accessory proteins are present simultaneously within replication factories making the process of translesion synthesis (TLS) far more complex than a simple primer elongation reaction.
As a consequence, we developed a methodology that allows TLS to be studied within cells (E. coli, yeast, mammalian cells) (Figure 4) (Baynton et al., 1998; Koffel-Schwartz et al., 1996) . Analysis of translesion synthesis in vivo is made possible by the use of double stranded plasmids containing a single adduct located within a short heteroduplex sequence. The strand containing the lesion and the opposite strand are called the target and marker strands respectively. Following transformation of the heteroduplex plasmid and its replication in E. coli or yeast cells, the presence, within individual colonies, of plasmids derived from the target and/or marker strands is detected by means of oligonucleotide hybridization with strand specific probes. We have verified that the presence of the heterology in the vicinity of the lesion does not affect the process of TLS, neither quantitatively nor qualitatively. A colony that hybridizes with the target and marker strand probes is scored as a TLS colony (Figure 4 , bottom left). Our assay also allows discriminating between error-free and mutagenic TLS events either phenotypically or by sequencing (Baynton et al., 1998; Koffel-Schwartz et al., 1996) . A colony that hybridizes only with the marker strand specific probe result from Damage Avoidance pathways, such as daughter strand gap repair by recombination or DNA polymerase template switch (Figure 4 , bottom, right). We will not discuss further the mechanisms of Damage Avoidance within the frame of this review.
The emerging complexity of TLS pathways in vivo
The extent and specificity of the bypass of defined lesions in intact cells was analysed by implementing the methodology outlined above. In E. coli or yeast cells, the availability of mutants in relevant genes (i.e. Figure 4 Analysis of TLS in vivo. An experimental strategy that allows TLS and mutagenesis to be analysed qualitatively and quantitatively in living cells is outlined. A plasmid with a single lesion (red square) in the target strand (in red) located within a short heteroduplex sequence formed by 4-nucleotide bulge in the marker strand (in green) is shown as an example. After transformation and replication in bacterial or yeast cells, individual colonies are analysed by oligonucleotide hybridization. A membrane with two colonies is shown as an example. The left hand side colony which responds to both target and marker strand probes is scored as a colony resulting from a TLS event. The nature of the TLS event (i.e. error-free or mutagenic) is further assessed by sequencing for example. A colony that only hybridizes with the marker strand probe (right hand side colony) results from a Damage Avoidance event. In a typical experiment &1000 colonies are analysed to quantitatively estimate the percentage of error-free and mutagenic TLS events among the total number of colonies. The effects of mutant strains (i.e. defective in a one or several DNA polymerase genes) or different physiological conditions (i.e. induction or not of the SOS response) upon TLS and mutagenesis can thus be assessed DNA polymerase genes) made it possible to determine the genetic requirements of defined TLS pathways. In E. coli, it was found that all three SOS-inducible DNA polymerases (Pol II, IV and V) may be involved in TLS and mutagenesis (see below; Lenne-Samuel et al., 2000; Napolitano et al., 2000; Wagner et al., 2002) . As outlined in Figure 5 , some TLS pathways specifically involve one of the three polymerases; other lesions have an absolute requirement for a specific combination of two enzymes for their bypass ( Figure  5b -d,e) . Curiously some bulky lesion bypass pathways apparently can be achieved by Pol III holoenzyme on its own (Figure 5a -c) . In contrast, examples where two distinct polymerases are able to bypass a given lesion (functional redundancy) have also been observed (Figure 5c -e) . Genetic requirements of bypass pathways not only depend upon the chemical nature of the lesion but also upon the local sequence context within which the lesion is located. As it stands now, there is no simple rule that allows one to predict which polymerase or combination thereof will be involved in a given TLS pathway. It appears that in order to deal with the large diversity of existing DNA lesions, cells are endowed with a pool of DNA polymerases that can all potentially get access to the lesion terminus (Napolitano et al., 2000) . Depending upon the specific distortion that the lesion imposes upon the primer/terminus, one, several or a Figure 5 The diversity of genetic requirements of TLS pathways: examples in E. coli and S. cerevisiae. Quite surprisingly, the genetic requirements of TLS pathways appear to be rather complex and non-uniform, depending both upon the lesion itself and its sequence context. Bulky lesions may be bypassed by the replicative polymerase alone (G-AF, BaP) or may require an additional specific TLS polymerase (T(6-4)T, G-AAF in the GGG context), or may even require two specific TLS polymerases (BaP adduct). Other situations, where several polymerases can compete for the bypass of a single lesion, yielding distinct replication products have also been found in E. coli, (see text and Figure 6 ) Napolitano et al., 2000) and yeast cells (Bresson and Fuchs, 2002) specific combination of polymerases will be required for bypass. The outcome of a given bypass reaction, i.e. error-free or mutagenic, largely depends upon the polymerase that gained access to the lesion terminus. Below we will discuss data suggesting that at least in E. coli, a simple competition model among DNA polymerases may actually govern the access to a blocked DNA synthesis site.
In wild type S. cerevisiae, replication of a single T(6-4)T photoproduct produces error-free and mutagenic (3'-T?C transition) bypass products at about equal frequencies. Surprisingly, mutagenic bypass requires the action of Pol Z followed by Pol z, while error-free bypass involves another, not yet identified DNA polymerase and Pol z (Figure 5f ) (Bresson and Fuchs, 2002) . The involvement of multiple polymerases in lesion bypass in yeast has also been found for G-AAF adducts (Bresson and Fuchs, 2002) and AP sites (Haracska et al., 2001c) .
Polymerases can compete for the extension of a blocked replication intermediate: a simple competition?
As discussed above, examples where bypass of a given lesion may be performed by two different DNA polymerases have been discovered. Such a situation is particularly interesting if the two polymerases generate distinct bypass products, thus allowing the interaction between the two pathways to be investigated. In E. coli, bypass of a single AAF adduct located within the NarI sequence (GGCG AAF CC) (Figure 6 ), may be accomplished by Pol V or II yielding error-free (GGCGCC) or -2 frameshift (GGCC) bypass products respectively (Napolitano et al., 2000) . Modulation of the relative expression levels of polB (Pol II) versus umuDC (Pol V) genes in vivo, results in a corresponding modulation of the extent of frameshift versus error-free bypass pathways respectively . These data suggest that Pol II and V compete for the extension of the same replication intermediate (lesion terminus) that can adopt two isomeric conformations ( Figure  6 ). In its non-slipped conformation extension is achieved by Pol V yielding an error free bypass product. In contrast, the slipped conformation of the lesion terminus is efficiently extended by Pol II generating the -2 frameshift product (Figure 6 ). These data suggest that different DNA polymerases can gain access and compete for the extension of a common lesion terminus in vivo.
Recruiting DNA polymerases to the site of action: the pivotal role of the b-clamp, the replication processivity factor
All five E. coli DNA polymerases appear to interact with the replication processivity factor, the b-clamp (Hughes et al., 1991; Kim and McHenry, 1996; Lopez de Saro and O'Donnell, 2001; Tang et al., 2000; Wagner et al., 2000) . The three SOS-inducible DNA polymerases (II, IV and V) contain a short peptide (consensus motif: QLxLF) that was identified in a yeast two-hybrid screen to mediate their interaction with the b-clamp (Dalrymple et al., 2001) . As these three polymerases are known to be involved in lesion bypass, we wanted to analyse the functional role of Figure 6 Competing bypass pathways: a single AAF adduct may be bypassed in an error-free manner by Pol V or yield a -2 frameshift product when Pol II is involved Fuchs et al., 2001; Napolitano et al., 2000) . The insertion of C across the G-AAF lesion can be performed by the replicative DNA Pol III or by Pol V generating a key replication intermediate referred to as the lesion terminus. Given the local sequence context (i.e. the NarI site that contains a 5'-GpC dinucleotide repeat), the lesion terminus can exist in two conformations, non-slipped or slipped. Pol V efficiently extends the non-slipped conformation yielding an error-free replication product. In contrast, Pol II very efficiently elongates the slipped intermediate, thus generating a -2 frameshift mutation . Recent in vivo work has shown that the extent of error-free versus mutagenic bypass depends directly upon the level of expression of Pol V versus Pol II , suggesting that access to the lesion terminus depends primarily upon the enzymes respective concentration Figure 7 The DNA polymerase traffic during lesion bypass: is the processivity clamp acting as a 'tool-belt'? All E. coli DNA polymerases and many eukaryotic polymerases interact with their respective replication clamp (b-clamp or PCNA). We have recently shown that the capacity of all three SOS-inducible DNA polymerases (Pol II, IV and V) to function in TLS and mutagenesis in vivo strictly depends upon an intact interaction with the b-clamp that appears to be a common interaction platform (Becherel et al., 2002; Lenne-Samuel et al., 2002) . In the present cartoon, given the pseudo sixfold symmetry of the replication clamps several DNA polymerases are shown to be tethered to a single replication clamp. The replicative DNA polymerase (yellow) detaches (a) from the primer template when encountering a template lesion (red square) while one of the accessory TLS polymerases (green) grasps the template primer (b) trying to insert a nucleotide across the lesion site. Another TLS polymerase (blue) may be involved at the extension step (c) before the replicative polymerase resumes high fidelity and rapid DNA synthesis (d) their interaction with the processivity factor during TLS and mutagenesis. In all three genes (polB, dinB, umuDC) the b-interacting peptide is located distantly from the DNA polymerase motifs making it possible to abolish the polymerase/b-clamp interaction without affecting the polymerase function. By implementing the in vivo TLS assay outlined above, we have recently shown that all TLS activities associated with Pol II, IV and V strictly depend upon the integrity of their respective b-clamp binding motif (Becherel et al., 2002; Lenne-Samuel et al., 2002) . In the case of Pol II and IV, the b-clamp binding motif is located at the very C-terminus of the protein, making it easy to picture this peptide as a flexible tether that connects the polymerase to the clamp (Figure 7) . Given the pseudo-sixfold symmetry of the processivity factors, one may speculate that several DNA polymerases connect simultaneously onto a single clamp. The processivity factor would thus act as a 'tool-belt' enabling different polymerases to be present concurrently near the lesion site. As several eukaryotic DNA polymerases potentially involved in lesion bypass (Pol Z, k, i) have recently been shown to interact with eukaryotic processivity factor PCNA (Haracska et al., 2001a (Haracska et al., ,b, 2002 , one might conclude that the mechanism of clamp-mediated switching of polymerases has been evolutionary conserved.
As discussed, most if not all DNA polymerases need to be recruited to their site of action by virtue of specific interactions with the replication processivity factor, the b-clamp in E. coli or PCNA in eukaryotes (see earlier). Is there a specific recruitment procedure? Although much more work needs to be done to answer this important question, it appears unlikely that the recruitment procedure of a given polymerase is instructed by the type of lesion to be bypassed. Recruitment of polymerases to the site of action may solely depend upon their relative concentration and affinity for the processivity clamp. The capacity of the recruited polymerase to handle the specific structural distortion present in the substrate will determine whether or not a nucleotide will be added to the primer. If the polymerase present is unable to handle the defect it will dissociate and another polymerase may be recruited. In conclusion, we suggest a model based on a 'trial and error' mode of recruitment of the bypass polymerases to the lesion site.
A human disease that results from a defect in a lesion bypass polymerases: the XP-V paradox Xeroderma pigmentosum (XP) is a rare autosomal recessive human disorder that is characterized by extreme sensitivity to sunlight and high incidence of skin cancer. While most XP patients exhibit a defect in nucleotide excision repair, about 20% of patients, the so-called XP-variants (XP-V), have a normal excision repair system but are defective in their capacity to replicate lesion containing DNA. In 1999, XP-V cell extracts were found to be repaired in Translesion Synthesis , the molecular defect residing in the XPV gene (Johnson et al., 1999a; Masutani et al., 1999a,b) . The gene XPV is homologous to the yeast RAD30 gene, encoding Pol Z a member of the Y-family polymerases. XPV cells exhibit an increased frequency of UV-induced mutations. At first sight it seems paradoxical that a mutation that inactivates an error-prone DNA polymerase actually increases the mutation rate. It turns out that Pol z despite being a very low fidelity polymerase has an intrinsic high capacity to replicate accurately through TT cyclobutane dimers the major UV light induced DNA lesion. In the absence of Pol Z, TT cyclobutane dimers are replicated less efficiently though with an increased error rate by another DNA polymerase(s), thus conferring a mutator phenotype to XPV cells. It should be stressed that although Pol Z may have been selected by evolution to insert A's across the most abundant UV-induced lesion, the TT cyclobutane dimers, thus preventing mutations caused by this slowly repaired and abundant lesion, it is not able to replicate 'correctly' any type of DNA lesion. Indeed, as shown recently, the 'incorrect' bypass of the T(6-4)T lesions in S. cerevisiae, yielding 3'-T?C transitions, is mediated by Pol Z (Bresson and . XPV is the first example of a human disorder caused by a defect in damaged DNA replication. Given the large number of proteins involved in lesion bypass and other damage tolerance pathways, it appears likely that other disorders affecting such pathways will be discovered in the future.
